<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Surg Innov</journal-id>
      <journal-id journal-id-type="iso-abbrev">Surg Innov</journal-id>
      <journal-id journal-id-type="publisher-id">SRI</journal-id>
      <journal-id journal-id-type="hwp">spsri</journal-id>
      <journal-title-group>
        <journal-title>Surgical Innovation</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1553-3506</issn>
      <issn pub-type="epub">1553-3514</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22455975</article-id>
      <article-id pub-id-type="pmc">3758170</article-id>
      <article-id pub-id-type="doi">10.1177/1553350612438416</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1553350612438416</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Multimodal Imaging and Detection Strategy With 124 I-Labeled Chimeric
Monoclonal Antibody cG250 for Accurate Localization and Confirmation of Extent of Disease
During Laparoscopic and Open Surgical Resection of Clear Cell Renal Cell
Carcinoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Povoski</surname>
            <given-names>Stephen P.</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1-1553350612438416">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hall</surname>
            <given-names>Nathan C.</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1-1553350612438416">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Murrey</surname>
            <given-names>Douglas A.</given-names>
            <suffix>Jr</suffix>
          </name>
          <degrees>MD, MS</degrees>
          <xref ref-type="aff" rid="aff1-1553350612438416">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sharp</surname>
            <given-names>David S.</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1-1553350612438416">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hitchcock</surname>
            <given-names>Charles L.</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1-1553350612438416">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mojzisik</surname>
            <given-names>Cathy M.</given-names>
          </name>
          <degrees>RN, MS</degrees>
          <xref ref-type="aff" rid="aff1-1553350612438416">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bahnson</surname>
            <given-names>Eamonn E.</given-names>
          </name>
          <degrees>BA</degrees>
          <xref ref-type="aff" rid="aff1-1553350612438416">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Knopp</surname>
            <given-names>Michael V.</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1-1553350612438416">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martin</surname>
            <given-names>Edward W.</given-names>
            <suffix>Jr</suffix>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1-1553350612438416">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bahnson</surname>
            <given-names>Robert R.</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff1-1553350612438416">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-1553350612438416"><label>1</label>The Ohio State University Medical Center,
Columbus, OH, USA</aff>
      <author-notes>
        <corresp id="corresp1-1553350612438416">Stephen P. Povoski, Department of Surgery, The Ohio
State University Medical Center, N-924 Doan Hall, 410 West 10th Avenue, Columbus, OH
43210, USA Email: <email>stephen.povoski@osumc.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>2</month>
        <year>2013</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>2013</year>
      </pub-date>
      <volume>20</volume>
      <issue>1</issue>
      <fpage>59</fpage>
      <lpage>69</lpage>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2013</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder content-type="sage">SAGE Publications</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits non-commercial use, distribution,
and reproduction in any medium, provided the original work is properly
cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Renal cell carcinoma (RCC) accounts for approximately 85% to 90% of all primary kidney
malignancies, with clear cell RCC (ccRCC) constituting approximately 70% to 85% of all
RCCs. This study describes an innovative multimodal imaging and detection strategy that
uses <sup>124</sup>I-labeled chimeric monoclonal antibody G250 (<sup>124</sup>I-cG250) for
accurate preoperative and intraoperative localization and confirmation of extent of
disease for both laparoscopic and open surgical resection of ccRCC. Two cases presented
herein highlight how this technology can potentially guide complete surgical resection and
confirm complete removal of all diseased tissues. This innovative <sup>124</sup>I-cG250
(ie, <sup>124</sup>I-girentuximab) multimodal imaging and detection approach, which would
be clinically very useful to urologic surgeons, urologic medical oncologists, nuclear
medicine physicians, radiologists, and pathologists who are involved in the care of ccRCC
patients, holds great potential for improving the diagnostic accuracy, operative planning
and approach, verification of disease resection, and monitoring for evidence of disease
recurrence in ccRCC patients.</p>
      </abstract>
      <kwd-group>
        <kwd>image-guided surgery</kwd>
        <kwd>surgical oncology</kwd>
        <kwd>urology</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="section1-1553350612438416">
      <title>Introduction</title>
      <p>Renal cell carcinoma (RCC), which arises from the renal tubular epithelial cells,<sup><xref ref-type="bibr" rid="bibr1-1553350612438416">1</xref><xref ref-type="bibr" rid="bibr2-1553350612438416"/><xref ref-type="bibr" rid="bibr3-1553350612438416"/>-<xref ref-type="bibr" rid="bibr4-1553350612438416">4</xref></sup> accounts for approximately
85% to 90% of all primary kidney malignancies.<sup><xref ref-type="bibr" rid="bibr5-1553350612438416">5</xref><xref ref-type="bibr" rid="bibr6-1553350612438416"/>-<xref ref-type="bibr" rid="bibr7-1553350612438416">7</xref></sup> Clear cell RCC
(ccRCC) constitutes approximately 70% to 85% of all RCCs, followed by papillary RCC (8% to
15%), chromophobe RCC (2% to 5%), and a variety of other rare histologic subtypes.<sup><xref ref-type="bibr" rid="bibr8-1553350612438416">8</xref><xref ref-type="bibr" rid="bibr9-1553350612438416"/><xref ref-type="bibr" rid="bibr10-1553350612438416"/><xref ref-type="bibr" rid="bibr11-1553350612438416"/><xref ref-type="bibr" rid="bibr12-1553350612438416"/><xref ref-type="bibr" rid="bibr13-1553350612438416"/>-<xref ref-type="bibr" rid="bibr14-1553350612438416">14</xref></sup></p>
      <p>In 1986, the IgG monoclonal antibody (mAb) Grawitz 250 (G250) was first described in the
literature by Oosterwijk et al<sup><xref ref-type="bibr" rid="bibr15-1553350612438416">15</xref>,<xref ref-type="bibr" rid="bibr16-1553350612438416">16</xref></sup> at the
University of Leiden in The Netherlands. Of historical interest, the basis of the name
Grawitz 250 is best explained by the developer of this mAb (Egbert Oosterwijk, personal
communication, July 11 and October 26, 2011). Mice were immunized with kidney tumor
homogenates, and all the hybridoma clones derived from the mice were named in consecutive
series with the letter G, followed by a number. The letter G was selected by Oosterwijk to
stand for Grawitz, in recognition of Paul Albert Grawitz (1850-1932), a German pathologist
and professor at the University of Greifswald from 1886 to 1921, who is credited in the
urologic literature with the first description of RCC in 1883 (ie, Grawitz&#x2019;s
tumor).<sup><xref ref-type="bibr" rid="bibr17-1553350612438416">17</xref>,<xref ref-type="bibr" rid="bibr18-1553350612438416">18</xref></sup> The number 250 simply
represented the fact that this particular hybridoma clone was the 250th hybridoma clone
derived from mice immunized with kidney tumor homogenates, thus forming the basis of the
derivation for the name Grawitz 250 (ie, G250). Even at its inception in 1986, Oosterwijk et
al<sup><xref ref-type="bibr" rid="bibr15-1553350612438416">15</xref></sup> clearly
recognized the great potential of G250 for radioimmunoimaging.</p>
      <p>Monoclonal antibody G250 recognizes the antigen carbonic anhydrase IX (CA IX).<sup><xref ref-type="bibr" rid="bibr16-1553350612438416">16</xref>,<xref ref-type="bibr" rid="bibr19-1553350612438416">19</xref></sup> CA IX antigen is a cytosolic transmembrane
glycoprotein.<sup><xref ref-type="bibr" rid="bibr19-1553350612438416">19</xref><xref ref-type="bibr" rid="bibr20-1553350612438416"/>-<xref ref-type="bibr" rid="bibr21-1553350612438416">21</xref></sup> It represents one of many carbonic
anhydrase enzymes that are involved in catalyzing the reaction CO<sub>2</sub> +
H<sub>2</sub>O &#x2194; HCO<sub>3</sub><sup>&#x2212;</sup> + H<sup>+</sup>, a process ultimately
important in the regulation of proton flux in cells and in pH regulation.<sup><xref ref-type="bibr" rid="bibr19-1553350612438416">19</xref>,<xref ref-type="bibr" rid="bibr20-1553350612438416">20</xref></sup> The catalytic site for CA IX is located
extracellularly, where it is involved in creating an acidic microenvironment.<sup><xref ref-type="bibr" rid="bibr19-1553350612438416">19</xref>,<xref ref-type="bibr" rid="bibr22-1553350612438416">22</xref></sup> CA IX expression has been shown to be
induced by hypoxia,<sup><xref ref-type="bibr" rid="bibr23-1553350612438416">23</xref>,<xref ref-type="bibr" rid="bibr24-1553350612438416">24</xref></sup> and it may have prognostic
implications for evaluating disease progression and response to therapy.<sup><xref ref-type="bibr" rid="bibr21-1553350612438416">21</xref>,<xref ref-type="bibr" rid="bibr25-1553350612438416">25</xref>,<xref ref-type="bibr" rid="bibr26-1553350612438416">26</xref></sup></p>
      <p>It is well established that CA IX antigen is constitutively expressed by 97% to 98% of all
ccRCC,<sup><xref ref-type="bibr" rid="bibr15-1553350612438416">15</xref>,<xref ref-type="bibr" rid="bibr16-1553350612438416">16</xref>,<xref ref-type="bibr" rid="bibr19-1553350612438416">19</xref>,<xref ref-type="bibr" rid="bibr21-1553350612438416">21</xref>,<xref ref-type="bibr" rid="bibr25-1553350612438416">25</xref>,<xref ref-type="bibr" rid="bibr27-1553350612438416">27</xref><xref ref-type="bibr" rid="bibr28-1553350612438416"/>-<xref ref-type="bibr" rid="bibr29-1553350612438416">29</xref></sup> in both primary and metastatic disease.<sup><xref ref-type="bibr" rid="bibr15-1553350612438416">15</xref>,<xref ref-type="bibr" rid="bibr16-1553350612438416">16</xref>,<xref ref-type="bibr" rid="bibr19-1553350612438416">19</xref>,<xref ref-type="bibr" rid="bibr21-1553350612438416">21</xref>,<xref ref-type="bibr" rid="bibr25-1553350612438416">25</xref>,<xref ref-type="bibr" rid="bibr27-1553350612438416">27</xref><xref ref-type="bibr" rid="bibr28-1553350612438416"/>-<xref ref-type="bibr" rid="bibr29-1553350612438416">29</xref></sup> Yet it is absent from normal kidney tissues, including normal adult
proximal tubular epithelial cells and fetal kidney tissue.<sup><xref ref-type="bibr" rid="bibr15-1553350612438416">15</xref>,<xref ref-type="bibr" rid="bibr16-1553350612438416">16</xref>,<xref ref-type="bibr" rid="bibr19-1553350612438416">19</xref>,<xref ref-type="bibr" rid="bibr27-1553350612438416">27</xref><xref ref-type="bibr" rid="bibr28-1553350612438416"/>-<xref ref-type="bibr" rid="bibr29-1553350612438416">29</xref></sup> Likewise, it is more minimally expressed or absent in other, much less
common renal epithelial neoplasms, including papillary RCC, chromophobe RCC, and
oncocytoma.<sup><xref ref-type="bibr" rid="bibr21-1553350612438416">21</xref></sup> A
variety of other tumors (ie, carcinomas of the uterine cervix, esophagus, colon, lung,
breast, brain, and vulva)<sup><xref ref-type="bibr" rid="bibr19-1553350612438416">19</xref>,<xref ref-type="bibr" rid="bibr27-1553350612438416">27</xref></sup> and
normal adult human tissues (ie, gastric mucosa, small intestinal mucosal crypts, liver, and
pancreatobiliary epithelium)<sup><xref ref-type="bibr" rid="bibr15-1553350612438416">15</xref>,<xref ref-type="bibr" rid="bibr21-1553350612438416">21</xref>,<xref ref-type="bibr" rid="bibr28-1553350612438416">28</xref>,<xref ref-type="bibr" rid="bibr29-1553350612438416">29</xref></sup> have been shown to have varying degrees of
CA IX expression. However, this is generally to a much lesser degree than is seen in ccRCC
and has greater heterogeneity. CA IX expression has not been demonstrated in normal heart,
lung, prostate, brain, muscle, peripheral blood, or placenta.<sup><xref ref-type="bibr" rid="bibr29-1553350612438416">29</xref></sup></p>
      <p>The use of mAb G250 for the targeting of CA IX in ccRCC, and the resultant potential
application related to radioimmunoimaging and various radioimmunotherapies, has long been
recognized by Oosterwijk and colleagues.<sup><xref ref-type="bibr" rid="bibr15-1553350612438416">15</xref>,<xref ref-type="bibr" rid="bibr16-1553350612438416">16</xref>,<xref ref-type="bibr" rid="bibr19-1553350612438416">19</xref>,<xref ref-type="bibr" rid="bibr30-1553350612438416">30</xref></sup> In 1993, Oosterwijk et al<sup><xref ref-type="bibr" rid="bibr31-1553350612438416">31</xref></sup> first reported on a phase
I trial of <sup>131</sup>I-labeled murine mAb G250 (mG250) administered intravenously to
preoperative patients with a clinical diagnosis of RCC, demonstrating safety and tumor
localization by radioimmunoscintigraphy using whole-body planar gamma camera imaging in all
patients with RCC expressing CA IX.<sup><xref ref-type="bibr" rid="bibr31-1553350612438416">31</xref></sup> However, the occurrence of human anti-mouse antibodies (HAMA) in all
the patients studied was thought to be a potential stumbling block for the use of mG250 for
serial radioimmunoimaging and multiple-treatment radioimmunotherapy. To minimize the
occurrence of HAMA response, a chimerized version of mAb G250 (cG250) was developed with the
same affinity and binding characteristics as mG250.<sup><xref ref-type="bibr" rid="bibr30-1553350612438416">30</xref>,<xref ref-type="bibr" rid="bibr32-1553350612438416">32</xref></sup> In 1997, Steffens et al<sup><xref ref-type="bibr" rid="bibr32-1553350612438416">32</xref></sup> reported on a phase I
trial of <sup>131</sup>I-cG250 administered intravenously to preoperative patients with a
clinical diagnosis of primary RCC, demonstrating safety and tumor localization by
radioimmunoscintigraphy using whole-body planar gamma camera imaging in all patients with
RCC expressing CA IX.<sup><xref ref-type="bibr" rid="bibr32-1553350612438416">32</xref></sup> However, subsequent similar trials using <sup>131</sup>I-cG250 to assess
radioimmunoscintigraphy with whole-body planar gamma camera imaging in patients with
metastatic RCC revealed more variability in the reported degree of successful disease
localization, ranging from 30% to 100%,<sup><xref ref-type="bibr" rid="bibr33-1553350612438416">33</xref><xref ref-type="bibr" rid="bibr34-1553350612438416"/><xref ref-type="bibr" rid="bibr35-1553350612438416"/><xref ref-type="bibr" rid="bibr36-1553350612438416"/>-<xref ref-type="bibr" rid="bibr37-1553350612438416">37</xref></sup> despite the fact that all these
publications were reported by the same group of authors. This greater variability in the
reported success of disease localization in patients with metastatic RCC may have been more
a reflection of the limitation of the variability in the gamma camera imaging technology
used during different phases of their investigations rather than that of the mAb G250
itself.</p>
      <p>With continued improvements in positron emission tomography/computed tomography (PET/CT)
technology, and the great potential for the use of the positron emitter <sup>124</sup>I with
this technology,<sup><xref ref-type="bibr" rid="bibr38-1553350612438416">38</xref>,<xref ref-type="bibr" rid="bibr39-1553350612438416">39</xref></sup> increased interest has
developed in the application of <sup>124</sup>I-cG250 for radioguided imaging and detection
of ccRCC.<sup><xref ref-type="bibr" rid="bibr40-1553350612438416">40</xref>,<xref ref-type="bibr" rid="bibr41-1553350612438416">41</xref></sup> In 2007, Divgi et
al<sup><xref ref-type="bibr" rid="bibr40-1553350612438416">40</xref></sup> first
reported on a pilot, phase I trial using intravenously administered <sup>124</sup>I-cG250 to
assess preoperative PET/CT localization of kidney tumors in patients scheduled for surgical
resection.<sup><xref ref-type="bibr" rid="bibr40-1553350612438416">40</xref></sup> They
found that 15 out of 16 (94%) ccRCCs were identified with <sup>124</sup> I-cG250 on PET/CT,
whereas all 9 non-ccRCCs were nonvisualized.<sup><xref ref-type="bibr" rid="bibr40-1553350612438416">40</xref></sup> In this regard, a larger,
multi-institutional phase III industry-sponsored clinical trial<sup><xref ref-type="bibr" rid="bibr42-1553350612438416">42</xref><xref ref-type="bibr" rid="bibr43-1553350612438416"/>-<xref ref-type="bibr" rid="bibr44-1553350612438416">44</xref></sup> using <sup>124</sup>I-cG250 (ie, <sup>124</sup>I-girentuximab), in
which The Ohio State University Medical Center (OSUMC) participated, has been subsequently
undertaken and patient accrual completed. The initial reported results from this
multi-institutional phase III industry-sponsored clinical trial have shown superiority of
<sup>124</sup>I-cG250 PET/CT imaging over that of diagnostic CT imaging in the diagnosis
of ccRCC.<sup><xref ref-type="bibr" rid="bibr44-1553350612438416">44</xref></sup></p>
      <p>Most recently, the use of handheld radiation detection probe technology for intraoperative
detection and localization of ccRCC using <sup>124</sup>I-cG250 and specimen PET/CT imaging
of resected surgical specimens has been described in the literature.<sup><xref ref-type="bibr" rid="bibr45-1553350612438416">45</xref><xref ref-type="bibr" rid="bibr46-1553350612438416"/>-<xref ref-type="bibr" rid="bibr47-1553350612438416">47</xref></sup> Along similar lines, a comprehensive methodology of multimodal imaging
and detection during <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG)-directed surgery
for patients with known or suspected <sup>18</sup>F-FDG-avid malignancies has been
previously described.<sup><xref ref-type="bibr" rid="bibr48-1553350612438416">48</xref><xref ref-type="bibr" rid="bibr49-1553350612438416"/><xref ref-type="bibr" rid="bibr50-1553350612438416"/>-<xref ref-type="bibr" rid="bibr51-1553350612438416">51</xref></sup> However, to date, an analogous multimodal imaging and detection
approach for <sup>124</sup>I-cG250-directed surgery is yet to be reported.</p>
      <p>To this point, the current report describes an innovative multimodal imaging and detection
methodology that uses <sup>124</sup>I-cG250 for accurate preoperative and intraoperative
localization and confirmation of extent of disease in both laparoscopic and open surgical
resection of ccRCC. The 2 cases presented herein highlight this technology. In one case,
this innovative strategy during a laparoscopic approach to ccRCC was instrumental in the
intraoperative identification of all diseased tissues (including a retroperitoneal lymph
node metastasis), in guiding complete surgical resection, and in the confirmation of
complete removal of all diseased tissues, thus allowing for successful laparoscopic
resection of both the primary and the metastatic sites of disease, which otherwise would not
have been technically feasible. In the other case, this innovative strategy during an open
right partial nephrectomy was instrumental in guiding complete surgical resection, in the
confirmation of complete removal of the tumor, and in the assessment of the kidney
parenchyma surgical resection margin.</p>
    </sec>
    <sec id="section2-1553350612438416">
      <title>Case Reports</title>
      <p>Both patients were enrolled at OSUMC in a multi-institutional phase III industry-sponsored
clinical trial (Wilex AG, Munich, Germany) comparing <sup>124</sup>I-based PET/CT imaging
versus diagnostic CT imaging for the detection of ccRCC in presurgical patients with renal
masses using <sup>124</sup>I-cG250.<sup><xref ref-type="bibr" rid="bibr42-1553350612438416">42</xref><xref ref-type="bibr" rid="bibr43-1553350612438416"/>-<xref ref-type="bibr" rid="bibr44-1553350612438416">44</xref></sup> As with any industry-sponsored clinical
trial conducted at OSUMC, the protocol was reviewed by the OSUMC Office of Responsible
Research Practices and reviewed and approved by the Western Institutional Review Board
(Olympia, WA). The radiolabeling of cG250 with <sup>124</sup>I was performed by IBA
Molecular North American (Richmond, VA).</p>
    </sec>
    <sec id="section3-1553350612438416">
      <title>Case 1</title>
      <p>A 60-year-old Caucasian male with a history of Ollier disease (a rare, nonhereditary,
sporadic disorder characterized by multiple intraosseous benign cartilaginous tumors)
presented with a right renal mass that was found at the time of a work-up for painless
hematuria. CT scan of the abdomen showed a 10.3 cm &#xD7; 7.6 cm &#xD7; 6.7 cm mass in the superior
pole of the right kidney, with infiltration into the posterior hilum of the upper renal pole
(<xref ref-type="fig" rid="fig1-1553350612438416">Figure 1</xref>). Retrograde cystoscopy
was completely negative.</p>
      <fig id="fig1-1553350612438416" position="float">
        <label>Figure 1.</label>
        <caption>
          <p>Diagnostic contrast-enhanced computed tomography (CT) of the abdomen (axial view)
showing a solid mass in the superior pole of the right kidney (<italic>red
arrow</italic>). This lesion demonstrated contrast enhancement with delayed washout
having a density prior to intravenous contrast of 30 Hounsfield units (HU), 150 HU after
contrast administration, and 58 HU in the excretion phase, suspicious for clear cell
renal cell carcinoma. In retrospect, the small retroperitoneal lymph node
(<italic>yellow arrow</italic>), which was not originally identified in the initial
interpretation of the prior contrast-enhanced CT of the abdomen or the
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography (PET)/CT, was later first
identified on <sup>124</sup>I-labeled chimeric monoclonal antibody G250 PET/CT and
proven to represent a retroperitoneal lymph node metastasis by light microscopy.</p>
        </caption>
        <graphic xlink:href="10.1177_1553350612438416-fig1"/>
      </fig>
      <p><sup>18</sup>F-FDG PET/CT imaging was performed during concomitant work-up of a suspicious
left femoral head/neck lesion related to the patient&#x2019;s Ollier disease. <sup>18</sup>F-FDG
PET/CT imaging was performed 89 minutes following intravenous administration of 15.3 mCi of
<sup>18</sup>F-FDG (<xref ref-type="fig" rid="fig2-1553350612438416">Figure 2</xref>). The
attenuation correction non-contrast-enhanced CT portion of the <sup>18</sup>F-FDG PET/CT
imaging showed a large mass arising from the superior pole of the right kidney, with
<sup>18</sup>F-FDG activity less than or equal to that of the normal <sup>18</sup>F-FDG
accumulation pattern within the remainder of either kidney. Mild, increased
<sup>18</sup>F-FDG activity was seen in the left femoral head and neck region. No obvious
sites of metastatic disease were originally identified in the initial interpretation of the
<sup>18</sup>F-FDG PET/CT imaging.</p>
      <fig id="fig2-1553350612438416" position="float">
        <label>Figure 2.</label>
        <caption>
          <p>Maximum-intensity projection image (A), axial <sup>18</sup>F-fluorodeoxyglucose
positron emission tomography (<sup>18</sup>F-FDG PET) images (B and E), axial
attenuation correction non-contrast-enhanced computed tomography (CT) images for
<sup>18</sup>F-FDG PET localization (C and F), and fused axial <sup>18</sup>F-FDG
PET/CT images (D and G) demonstrating physiologic renal <sup>18</sup>F-FDG activity (A,
B, D, E, and G; <italic>blue arrows</italic>) and showing a mass on the attenuation
correction non-contrast-enhanced CT (C; <italic>red arrow</italic>) that corresponds to
the mass seen on the prior diagnostic contrast-enhanced CT of the abdomen in <xref ref-type="fig" rid="fig1-1553350612438416">Figure 1</xref>. Note that the amount of
<sup>18</sup>F-FDG activity within the mass (A, B, and D; <italic>red arrows</italic>)
was less than or equal to that of the normal <sup>18</sup>F-FDG accumulation pattern
within the remainder of either kidney. In retrospect, the small retroperitoneal lymph
node (A, E, F, and G; <italic>yellow arrows</italic>), which was not originally
identified in the initial interpretation of the prior diagnostic contrast-enhanced CT of
the abdomen or the <sup>18</sup>F-FDG PET/CT, was later first identified on
<sup>124</sup>I-labeled chimeric monoclonal antibody G250 PET/CT and proven to
represent a retroperitoneal lymph node metastasis on light microscopy.</p>
        </caption>
        <graphic xlink:href="10.1177_1553350612438416-fig2"/>
      </fig>
      <p><sup>124</sup>I-cG250 PET/CT imaging was performed 4 days following intravenous
administration of 5.4 mCi of <sup>124</sup>I-cG250 (<xref ref-type="fig" rid="fig3-1553350612438416">Figure 3</xref>). <sup>124</sup>I-cG250 PET/CT imaging showed
increased <sup>124</sup>I-cG250 activity within the renal mass in the superior pole of the
right kidney, as well as increased <sup>124</sup>I-cG250 activity within a retroperitoneal
lymph node.</p>
      <fig id="fig3-1553350612438416" position="float">
        <label>Figure 3.</label>
        <caption>
          <p>Maximum-intensity projection image (A), axial <sup>124</sup>I-labeled chimeric
monoclonal antibody G250 (<sup>124</sup>I-cG250) positron emission tomography (PET)
images (B and E), axial attenuation correction non-contrast-enhanced computed tomography
(CT) for <sup>124</sup>I-cG250 PET localization (C and F), and fused axial
<sup>124</sup>I-cG250 PET/CT images (D and G) demonstrating significant
<sup>124</sup>I-cG250 activity in the superior portion of the right kidney (A, B, and D;
<italic>red arrows</italic>) that corresponds to the mass seen on the prior diagnostic
contrast-enhanced CT of the abdomen in <xref ref-type="fig" rid="fig1-1553350612438416">Figure 1</xref>. Note that there is little to no <sup>124</sup>I-cG250 accumulation
in the normal kidney (B, D, E, and G; <italic>blue arrows</italic>). Additionally, on
<sup>124</sup>I-cG250 PET/CT imaging, there is increased focal <sup>124</sup>I-cG250
activity within a small retroperitoneal lymph node (A, E, and G; <italic>yellow
arrows</italic>), which was not originally identified in the initial interpretation of
the prior diagnostic contrast-enhanced CT of the abdomen or the
<sup>18</sup>F-fluorodeoxyglucose PET/CT. This small retroperitoneal lymph node (A, E,
F, and G; <italic>yellow arrows</italic>) was later successfully identified and resected
with the aid of a laparoscopic gamma detection probe at the time of laparoscopic right
radical nephrectomy and retroperitoneal lymph node dissection.</p>
        </caption>
        <graphic xlink:href="10.1177_1553350612438416-fig3"/>
      </fig>
      <p>The patient was taken to the operating room and underwent a laparoscopic right radical
nephrectomy with retroperitoneal lymph node dissection. Intraoperatively, a laparoscopic
gamma detection probe (Neoprobe Model 2059, Neoprobe Corporation, Dublin, OH) was used to
localize and identify all sites of <sup>124</sup>I-cG250 uptake, to assist in the surgical
resection, and for confirmation of complete removal of all sites of increased
<sup>124</sup>I-cG250 activity. The laparoscopic gamma detection probe correctly identified
increased <sup>124</sup>I-cG250 activity, both within the primary tumor of the right kidney
and within the adjacent retroperitoneal lymph node tissues and provided confirmation of
successful laparoscopic surgical resection.</p>
      <p>The intact right radical nephrectomy specimen and the intact retroperitoneal lymph node
dissection specimen were imaged with <sup>124</sup>I-cG250 PET/CT imaging and underwent
subsequent standard pathology processing and microscopic evaluation (<xref ref-type="fig" rid="fig4-1553350612438416">Figure 4</xref>). <sup>124</sup>I-cG250 PET/CT imaging clearly
identified the sites of disease within the intact right radical nephrectomy specimen and the
intact retroperitoneal lymph node dissection specimen. Histopathologic evaluation of the
right nephrectomy specimen revealed an RCC (Fuhrman grade 3, 10.5 cm &#xD7; 7.4 cm &#xD7; 5.8 cm) of
the clear cell type with sarcomatoid features. It had surgical resection margins that were
negative, including Gerota&#x2019;s fascia, the renal vessels, and the distal ureter. A total of 5
regional lymph nodes were identified within the retroperitoneal lymph node dissection
specimen, with one lymph node metastasis identified and representing a lymph node nearly
completely replaced by a tumor that was initially recognized on the preoperative
<sup>124</sup>I-cG250 PET/CT imaging and resected with the assistance of the laparoscopic
gamma detection probe.</p>
      <fig id="fig4-1553350612438416" position="float">
        <label>Figure 4.</label>
        <caption>
          <p>Digital photograph of the intact right radical nephrectomy specimen (A) with
<sup>124</sup>I-labeled chimeric monoclonal antibody G250 (<sup>124</sup>I-cG250)
positron emission tomography (PET)/computed tomography (CT) three-dimensional (3D)
reconstruction (B) demonstrating a heterogeneous area of increased <sup>124</sup>I-cG250
activity and corresponding to the histopathologically proven clear cell renal cell
carcinoma primary tumor (C), as seen on light microscopy (hematoxylin and eosin
[H&amp;E]-stained, whole-mount slide, 0.4&#xD7; magnification). Digital photograph of the
intact retroperitoneal lymph node dissection specimen (D) with <sup>124</sup>I-cG250
PET/CT 3D reconstruction (E) demonstrating focal increased <sup>124</sup>I-cG250
activity and a corresponding single lymph node that was found to contain
histopathologically proven metastatic clear cell renal cell carcinoma (F), as seen on
light microscopy (H&amp;E-stained, whole-mount slide, 0.3&#xD7; magnification).</p>
        </caption>
        <graphic xlink:href="10.1177_1553350612438416-fig4"/>
      </fig>
      <p>The patient had a relatively uneventful postoperative course and was discharged to home on
postoperative day 1. Two weeks later, the patient subsequently underwent an uneventful left
proximal femur hemiarthroplasty, which showed a low-grade cartilaginous neoplasm, consistent
with his Ollier disease. The patient then went on to participate in the ASSURE (ECOG 2805)
clinical trial, representing a randomized, double-blind, multi-institutional, phase III
clinical trial comparing adjuvant sorafenib versus adjuvant sunitinib versus placebo in
patients with resected RCC. At the time of this publication&#x2014;30 months after the patient&#x2019;s
previous laparoscopic right radical nephrectomy and retroperitoneal lymph node
dissection&#x2014;the patient is without evidence of disease.</p>
    </sec>
    <sec id="section4-1553350612438416">
      <title>Case 2</title>
      <p>A 39-year-old Caucasian female with a previous history of renal calculi presented for
evaluation of right flank pain. Ultrasound of the abdomen showed a 1.9 cm &#xD7; 1.6 cm &#xD7; 1.4 cm
solid-appearing lesion in the inferior pole of the right kidney. CT of the abdomen showed a
2.0 cm &#xD7; 1.9 cm &#xD7; 1.9 cm intraparenchymal mass within the posterior cortex of the inferior
pole of the right kidney (<xref ref-type="fig" rid="fig5-1553350612438416">Figure
5</xref>).</p>
      <fig id="fig5-1553350612438416" position="float">
        <label>Figure 5.</label>
        <caption>
          <p>Diagnostic contrast-enhanced computed tomography (CT) of the abdomen (axial view)
showing a solid mass in the inferior pole of the right kidney (<italic>red
arrow</italic>). This lesion demonstrated contrast enhancement with delayed washout
having a density prior to intravenous contrast of 39 Hounsfield units (HU), 111 HU after
contrast administration, and 83 HU in the excretion phase, suspicious for clear cell
renal cell carcinoma.</p>
        </caption>
        <graphic xlink:href="10.1177_1553350612438416-fig5"/>
      </fig>
      <p><sup>124</sup>I-cG250 PET/CT imaging was performed 5 days following intravenous
administration of 5.2 mCi of <sup>124</sup>I-cG250 (<xref ref-type="fig" rid="fig6-1553350612438416">Figure 6</xref>). <sup>124</sup>I PET/CT imaging showed
increased <sup>124</sup>I-cG250 activity within the renal mass in the inferior pole of the
right kidney.</p>
      <fig id="fig6-1553350612438416" position="float">
        <label>Figure 6.</label>
        <caption>
          <p>Maximum-intensity projection image (A), axial <sup>124</sup>I-labeled chimeric
monoclonal antibody G250 (<sup>124</sup>I-cG250) positron emission tomography (PET)
image (B), axial attenuation correction non-contrast-enhanced computed tomography (CT)
for <sup>124</sup>I-cG250 PET localization (C), and fused axial <sup>124</sup>I-cG250
PET/CT image (D) demonstrating increased <sup>124</sup>I-cG250 activity in the inferior
pole of the right kidney (A, B, and D; <italic>red arrows</italic>) that corresponds to
the mass seen on the prior diagnostic contrast-enhanced CT of the abdomen in <xref ref-type="fig" rid="fig5-1553350612438416">Figure 5</xref>. Note that there is little
to no <sup>124</sup>I-cG250 activity in the remainder of either kidney.</p>
        </caption>
        <graphic xlink:href="10.1177_1553350612438416-fig6"/>
      </fig>
      <p>The patient was taken to the operating room and underwent an open right partial nephrectomy
of the inferior pole of the right kidney. At the discretion of the surgeon, an
intraoperative gamma detection probe was not used in this case.</p>
      <p>The intact and bisected right partial nephrectomy specimens were imaged with
<sup>124</sup>I PET/CT imaging (<xref ref-type="fig" rid="fig7-1553350612438416">Figure
7</xref>). <sup>124</sup>I-cG250 PET/CT imaging clearly identified the tumor size and
location within the intact and bisected specimens and the relationship of the tumor to the
parenchymal surgical resection margin surface within the bisected specimen.</p>
      <fig id="fig7-1553350612438416" position="float">
        <label>Figure 7.</label>
        <caption>
          <p>Digital photograph of the intact right partial nephrectomy specimen (A), with computed
tomography (CT) three-dimensional (3D) reconstruction (B) demonstrating an ovoid
hyperdensity in the center of the intact specimen and with <sup>124</sup>I-labeled
chimeric monoclonal antibody G250 (<sup>124</sup>I-cG250) positron emission tomography
(PET)/CT 3D reconstruction (C) demonstrating an ovoid area of increased
<sup>124</sup>I-cG250 activity in the center of the intact specimen. Digital photograph
of the bisected right partial nephrectomy specimen, grossly demonstrating an ovoid tumor
mass (D). The cut-surface edge of the parenchymal surgical resection margin of the right
partial nephrectomy specimen was painted with blue ink prior to bisection. The black
dashed line in panel A corresponds to the plane of bisection of the right partial
nephrectomy specimen in panel D. CT 3D reconstruction of the bisected right partial
nephrectomy specimen (E) demonstrates an ovoid hyperdensity in the center of the
bisected specimen. The <sup>124</sup>I-cG250 PET/CT 3D reconstruction of the bisected
right partial nephrectomy specimen (F) demonstrates an ovoid area of increased
<sup>124</sup>I-cG250 activity, of a similar shape and distribution, in the center of
the bisected specimen. The white dotted line in panels D, E, and F represents the
cut-surface edge of the blue-inked parenchymal surgical resection margin of the bisected
right partial nephrectomy specimen (D). Note that the CT 3D reconstruction image of the
bisected specimen (E) and the <sup>124</sup>I-cG250 3D PET/CT reconstruction image of
the bisected specimen (F) both demonstrate that the ovoid hyperdensity and area of
intense <sup>124</sup>I-cG250 activity, respectively, do not extend to the parenchymal
surgical resection margin surface. Digital microphotograph (G) of the 1.7 cm &#xD7; 1.5 cm &#xD7;
1.4 cm clear cell renal cell carcinoma with a negative parenchymal surgical resection
margin, as seen on light microscopy (hematoxylin and eosin&#x2013;stained, whole-mount slide,
0.3&#xD7; magnification). The black dotted line in panel G represents the cut-surface edge of
the parenchymal surgical resection margin of the bisected right partial nephrectomy
specimen (D).</p>
        </caption>
        <graphic xlink:href="10.1177_1553350612438416-fig7"/>
      </fig>
      <p>The right partial nephrectomy specimen underwent subsequent standard pathology processing
and microscopic evaluation (<xref ref-type="fig" rid="fig7-1553350612438416">Figure
7</xref>). Histopathologic evaluation of the right partial nephrectomy specimen revealed an
RCC (Fuhrman grade 2, 1.7 cm &#xD7; 1.5 cm &#xD7; 1.4 cm) of the clear cell type. It had negative
surgical resection margins, with the closest distance measuring 0.7 cm from the inked
parenchymal surgical resection margin surface of the right partial nephrectomy specimen,
which correlated well with the <sup>124</sup>I-cG250 PET/CT image of the bisected right
partial nephrectomy specimen.</p>
      <p>The patient had a relatively uneventful postoperative course and was discharged to home on
postoperative day 2. The patient required no postoperative adjuvant therapies. At the time
of this publication&#x2014;36 months after her previous open right partial nephrectomy&#x2014;the patient
is without evidence of disease.</p>
    </sec>
    <sec sec-type="discussion" id="section5-1553350612438416">
      <title>Discussion</title>
      <p><sup>18</sup>F-FDG PET/CT imaging is currently considered the standard of care for the
molecular imaging of many solid malignancies.<sup><xref ref-type="bibr" rid="bibr52-1553350612438416">52</xref><xref ref-type="bibr" rid="bibr53-1553350612438416"/><xref ref-type="bibr" rid="bibr54-1553350612438416"/><xref ref-type="bibr" rid="bibr55-1553350612438416"/><xref ref-type="bibr" rid="bibr56-1553350612438416"/>-<xref ref-type="bibr" rid="bibr57-1553350612438416">57</xref></sup> However, <sup>18</sup>F-FDG PET/CT imaging has the inherent limitation
of being non-cancer-specific, resulting in the accumulation of <sup>18</sup>F-FDG in many
non-cancer-bearing tissues, including accumulation within tissues representing benign
disease processes (ie, infection, inflammation, and trauma) and within normal tissues (ie,
brain, heart, mucosa and smooth muscle of the stomach, small intestines and colon, thyroid,
liver, spleen, kidneys, ureters, and bladder) that have a normal physiologic propensity to
accumulate <sup>18</sup>F-FDG.<sup><xref ref-type="bibr" rid="bibr52-1553350612438416">52</xref><xref ref-type="bibr" rid="bibr53-1553350612438416"/><xref ref-type="bibr" rid="bibr54-1553350612438416"/><xref ref-type="bibr" rid="bibr55-1553350612438416"/>-<xref ref-type="bibr" rid="bibr56-1553350612438416">56</xref>,<xref ref-type="bibr" rid="bibr58-1553350612438416">58</xref><xref ref-type="bibr" rid="bibr59-1553350612438416"/><xref ref-type="bibr" rid="bibr60-1553350612438416"/><xref ref-type="bibr" rid="bibr61-1553350612438416"/><xref ref-type="bibr" rid="bibr62-1553350612438416"/><xref ref-type="bibr" rid="bibr63-1553350612438416"/><xref ref-type="bibr" rid="bibr64-1553350612438416"/>-<xref ref-type="bibr" rid="bibr65-1553350612438416">65</xref></sup> As a result of this inherent limitation of
<sup>18</sup>F-FDG, the specificity and sensitivity of <sup>18</sup>F-FDG PET/CT for
cancer imaging have been negatively affected. This is especially evident for certain cancer
types (ie, RCC, bladder cancer, and prostate cancer) that typically are located in close
proximity to anatomic structures with high physiologic <sup>18</sup>F-FDG activity (ie,
kidneys, ureters, and bladder). This negative effect on the specificity and sensitivity of
<sup>18</sup>F-FDG PET/CT for cancer imaging is truly a reflection of an intrinsic
challenge of such imaging as it relates to the issue of background activity and is not
necessarily a reflection of the available signal.<sup><xref ref-type="bibr" rid="bibr66-1553350612438416">66</xref></sup> This intrinsic background activity dilemma
remains the major limiting factor of <sup>18</sup>F-FDG PET/CT for cancer imaging.</p>
      <p>In this specific regard, the background activity challenges can be significantly improved
on for PET/CT imaging of cancer when one considers coupling a positron-emitting
radionuclide, such as <sup>124</sup>I, with a molecular targeting agent that is cancer
specific, such as cG250, which is nearly ubiquitously and constitutively expressed by all
ccRCCs but has low to no expression in most normal adult human tissues. There are exceptions
to this rule in normal adult human tissues, such as gastric mucosa, small intestinal mucosal
crypts, liver, and pancreatobiliary epithelium, to which the molecular targeting agent cG250
can bind, but generally to more varying and less intense degrees than seen with
ccRCC.<sup><xref ref-type="bibr" rid="bibr15-1553350612438416">15</xref>,<xref ref-type="bibr" rid="bibr21-1553350612438416">21</xref>,<xref ref-type="bibr" rid="bibr28-1553350612438416">28</xref>,<xref ref-type="bibr" rid="bibr29-1553350612438416">29</xref></sup> To his great credit, the potential of mAb
G250 for targeting CA IX in ccRCC and for use in various radioimmunoimaging and
radioimmunotherapy applications has long been recognized by Oosterwijk.<sup><xref ref-type="bibr" rid="bibr15-1553350612438416">15</xref>,<xref ref-type="bibr" rid="bibr16-1553350612438416">16</xref>,<xref ref-type="bibr" rid="bibr19-1553350612438416">19</xref>,<xref ref-type="bibr" rid="bibr30-1553350612438416">30</xref></sup></p>
      <p>The development of an innovative multimodal imaging and detection strategy that effectively
uses <sup>124</sup>I-cG250 for the management of ccRCC would be clinically very useful to
urologic surgeons, urologic medical oncologists, nuclear medicine physicians, radiologists,
and pathologists who are involved in the care of ccRCC patients.<sup><xref ref-type="bibr" rid="bibr46-1553350612438416">46</xref></sup> This innovative <sup>124</sup>I-cG250
multimodal imaging and detection methodology could potentially be instrumental in
(<italic>a</italic>) accurately localizing and identifying all sites of disease and the
extent of disease, (<italic>b</italic>) assisting in the surgical resection and confirmation
of complete removal of all sites of disease, and (<italic>c</italic>) monitoring patients
for evidence of recurrence of disease after previous surgical resection. Such an innovative
<sup>124</sup>I-cG250 multimodal imaging and detection strategy would be useful for
accurate preoperative and intraoperative localization and confirmation of complete removal
of all sites of disease during both laparoscopic and open surgical resection of ccRCC, as
well as for cases with or without known/suspected regional lymph node involvement. In
particular, as it pertains to laparoscopic surgical resection of patients with ccRCC, this
<sup>124</sup>I-cG250 multimodal imaging and detection strategy may allow for
identification and complete surgical resection of the known primary tumor and of any sites
of occult disease (ie, regional lymph node metastases) by a minimally invasive laparoscopic
surgical approach, which otherwise would not be technically feasible without a specific
molecular targeting approach with <sup>124</sup>I-cG250. Likewise, as it pertains to
attempted partial nephrectomy by either a laparoscopic or an open surgical resection
approach for patients with early-stage ccRCC, this <sup>124</sup>I-cG250 multimodal imaging
and detection strategy may improve the success rate of complete surgical resection by
assisting the urologic surgeon and the pathologist in the assessment of the kidney
parenchyma surgical resection margin. Last, as it pertains to radical nephrectomy by either
a laparoscopic or an open surgical resection approach for patients with more advanced but
still potentially surgically resectable carcinoma (ie, with larger primary tumors and/or
bulky regional lymph node involvement), this <sup>124</sup>I-cG250 multimodal imaging and
detection strategy may be of assistance to the urologic surgeon for intraoperative guidance
on the exact extent of disease and for confirmation of complete surgical resection.</p>
    </sec>
    <sec sec-type="conclusions" id="section6-1553350612438416">
      <title>Conclusions</title>
      <p>Herein, an innovative multimodal imaging and detection strategy that uses
<sup>124</sup>I-cG250 for accurate preoperative and intraoperative localization and
confirmation of extent of disease for ccRCC has been described. In one case, the use of this
innovative strategy during a laparoscopic approach to ccRCC was instrumental in the
intraoperative identification of all diseased tissues (including a retroperitoneal lymph
node metastasis), in guiding complete surgical resection, and in the confirmation of
complete removal of all diseased tissues, thus allowing for successful laparoscopic
resection of both the primary and the metastatic sites of disease, which otherwise would not
have been technically feasible. In the other case, this innovative strategy during an open
right partial nephrectomy was instrumental in guiding complete surgical resection, in the
confirmation of complete removal of the tumor, and in the assessment of the kidney
parenchyma surgical resection margin. This multimodal approach, which would be clinically
very useful to urologic surgeons, urologic medical oncologists, nuclear medicine physicians,
radiologists, and pathologists who are involved in the care of ccRCC patients, holds great
potential for improving the diagnostic accuracy, operative planning and approach,
verification of disease resection, and monitoring for evidence of disease recurrence in
patients with ccRCC.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>The authors are very grateful to Darlene M. Meeks of The Ohio State University Medical
Center (OSUMC) Radiology 3D Lab for her assistance with CT 3D image reconstruction, used to
portray selected images in <xref ref-type="fig" rid="fig4-1553350612438416">Figure 4</xref>
and <xref ref-type="fig" rid="fig7-1553350612438416">Figure 7</xref>; to William Bennett,
Deborah Hurley, Wendy Wilt, Marlene Wagonrod, Nichole Storey, and Carley Hartings from the
Department of Radiology at OSUMC; to George Hinkle, Sonny Edwards, Rodd Reinhart, and Aaron
Haynam from the OSUMC Nuclear Pharmacy; and to Debra Zynger and Lawrence De Renne from the
Department of Pathology at OSUMC.</p>
    </ack>
    <fn-group>
      <fn fn-type="other">
        <p><bold>Authors&#x2019; Note:</bold> The authors had full control of the design of this study, data analysis/interpretation,
writing of this article, and decision to submit the article for publication.</p>
      </fn>
      <fn fn-type="conflict">
        <p><bold>Declaration of Conflicting Interests:</bold> As disclosure of financial support for the publication of this article, we acknowledge
that this study was supported by funds from IBA Molecular North America, Inc. (Dulles,
Virginia) and Wilex AG (Munich, Germany) for payment of the fee for publication of the
color figures and for payment of the fee for SAGE Choice.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the research,
authorship, and/or publication of this article: This study was supported by funds from IBA
Molecular North America, Inc. (Dulles, Virginia) and Wilex AG (Munich, Germany) for
payment of the fees for publication of the color figures and for SAGE Choice.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-1553350612438416">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pilcher</surname><given-names>JT</given-names></name></person-group>
<article-title>Carcinoma of the kidney</article-title>. <source>Ann
Surg</source>.
<year>1921</year>;<volume>73</volume>:<fpage>301</fpage>-<lpage>309</lpage><pub-id pub-id-type="pmid">17864425</pub-id></mixed-citation>
      </ref>
      <ref id="bibr2-1553350612438416">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oberling</surname><given-names>C</given-names></name><name><surname>Riviere</surname><given-names>M</given-names></name><name><surname>Haguenau</surname><given-names>F</given-names></name></person-group>
<article-title>Ultrastructure of the clear cells in renal carcinomas and
its importance for the demonstration of their renal origin</article-title>.
<source>Nature</source>.
<year>1960</year>;<volume>186</volume>:<fpage>402</fpage>-<lpage>403</lpage><pub-id pub-id-type="pmid">14428164</pub-id></mixed-citation>
      </ref>
      <ref id="bibr3-1553350612438416">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braunstein</surname><given-names>H</given-names></name><name><surname>Adelman</surname><given-names>JU</given-names></name></person-group>
<article-title>Histochemical study of the enzymatic activity of human
neoplasms. II. Histogenesis of renal cell carcinoma</article-title>.
<source>Cancer</source>.
<year>1966</year>;<volume>19</volume>:<fpage>935</fpage>-<lpage>938</lpage><pub-id pub-id-type="pmid">4161094</pub-id></mixed-citation>
      </ref>
      <ref id="bibr4-1553350612438416">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wallace</surname><given-names>AC</given-names></name><name><surname>Nairn</surname><given-names>RC</given-names></name></person-group>
<article-title>Renal tubular antigens in kidney tumors</article-title>.
<source>Cancer</source>.
<year>1972</year>;<volume>29</volume>:<fpage>977</fpage>-<lpage>981</lpage><pub-id pub-id-type="pmid">4335980</pub-id></mixed-citation>
      </ref>
      <ref id="bibr5-1553350612438416">
        <label>5.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Eble</surname><given-names>JN</given-names></name><name><surname>Togashi</surname><given-names>K</given-names></name><name><surname>Pisani</surname><given-names>P</given-names></name></person-group>
<article-title>Renal cell carcinoma</article-title>. In <person-group person-group-type="editor"><name><surname>Eble</surname><given-names>JN</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name><name><surname>Epstein</surname><given-names>JI</given-names></name><name><surname>Sesterhenn</surname><given-names>IA</given-names></name></person-group>, ed. <source>World Health Organization Classification of Tumours:
Pathology and Genetics of Tumours of the Urinary System and Male Genital
Organs</source>. <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>IARC
Press</publisher-name>;
<year>2004</year>:<fpage>10</fpage>-<lpage>12</lpage></mixed-citation>
      </ref>
      <ref id="bibr6-1553350612438416">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<collab>National Cancer Institute, Division of Cancer Control and Population Science,
Surveillance Research Program, Cancer Statistics Branch</collab>
<article-title>SEER
Program Public Use Data Tapes 1973-2002</article-title>. <month>4</month>
<year>2005</year></mixed-citation>
      </ref>
      <ref id="bibr7-1553350612438416">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lipworth</surname><given-names>L</given-names></name><name><surname>Tarone</surname><given-names>RE</given-names></name><name><surname>McLaughlin</surname><given-names>JK</given-names></name></person-group>
<article-title>The epidemiology of renal cell carcinoma</article-title>.
<source>J Urol</source>. <year>2006</year>;<volume>176</volume>(<issue>6 pt 1</issue>):
<fpage>2353</fpage>-<lpage>2358</lpage><pub-id pub-id-type="pmid">17085101</pub-id></mixed-citation>
      </ref>
      <ref id="bibr8-1553350612438416">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>G</given-names></name><name><surname>Akhtar</surname><given-names>M</given-names></name><name><surname>Beckwith</surname><given-names>BJ</given-names></name><etal/></person-group>
<article-title>The Heidelberg classification of renal cell
tumours</article-title>. <source>J Pathol</source>.
<year>1997</year>;<volume>183</volume>:<fpage>131</fpage>-<lpage>133</lpage><pub-id pub-id-type="pmid">9390023</pub-id></mixed-citation>
      </ref>
      <ref id="bibr9-1553350612438416">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Amin</surname><given-names>MB</given-names></name><name><surname>Amin</surname><given-names>MB</given-names></name><name><surname>Tamboli</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Prognostic impact of histologic subtyping of adult renal
epithelial neoplasms: an experience of 405 cases</article-title>. <source>Am J Surg
Pathol</source>.
<year>2002</year>;<volume>26</volume>:<fpage>281</fpage>-<lpage>291</lpage><pub-id pub-id-type="pmid">11859199</pub-id></mixed-citation>
      </ref>
      <ref id="bibr10-1553350612438416">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Renshaw</surname><given-names>AA</given-names></name></person-group>
<article-title>Subclassification of renal cell neoplasms: an update for
the practising pathologist</article-title>. <source>Histopathology</source>.
<year>2002</year>;<volume>41</volume>:<fpage>283</fpage>-<lpage>300</lpage><pub-id pub-id-type="pmid">12383210</pub-id></mixed-citation>
      </ref>
      <ref id="bibr11-1553350612438416">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheville</surname><given-names>JC</given-names></name><name><surname>Lohse</surname><given-names>CM</given-names></name><name><surname>Zincke</surname><given-names>H</given-names></name><name><surname>Weaver</surname><given-names>AL</given-names></name><name><surname>Blute</surname><given-names>ML</given-names></name></person-group>
<article-title>Comparisons of outcome and prognostic features among
histologic subtypes of renal cell carcinoma</article-title>. <source>Am J Surg
Pathol</source>.
<year>2003</year>;<volume>27</volume>:<fpage>612</fpage>-<lpage>624</lpage><pub-id pub-id-type="pmid">12717246</pub-id></mixed-citation>
      </ref>
      <ref id="bibr12-1553350612438416">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gudbjartsson</surname><given-names>T</given-names></name><name><surname>Hardarson</surname><given-names>S</given-names></name><name><surname>Petursdottir</surname><given-names>V</given-names></name><name><surname>Thoroddsen</surname><given-names>A</given-names></name><name><surname>Magnusson</surname><given-names>J</given-names></name><name><surname>Einarsson</surname><given-names>GV</given-names></name></person-group>
<article-title>Histological subtyping and nuclear grading of renal cell
carcinoma and their implications for survival: a retrospective nation-wide study of 629
patients</article-title>. <source>Eur Urol</source>.
<year>2005</year>;<volume>48</volume>:<fpage>593</fpage>-<lpage>600</lpage><pub-id pub-id-type="pmid">15964127</pub-id></mixed-citation>
      </ref>
      <ref id="bibr13-1553350612438416">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prasad</surname><given-names>SR</given-names></name><name><surname>Humphrey</surname><given-names>PA</given-names></name><name><surname>Catena</surname><given-names>JR</given-names></name><etal/></person-group>
<article-title>Common and uncommon histologic subtypes of renal cell
carcinoma: imaging spectrum with pathologic correlation</article-title>.
<source>Radiographics</source>.
<year>2006</year>;<volume>26</volume>:<fpage>1795</fpage>-<lpage>1806</lpage>;
discussion 1806-1810.<pub-id pub-id-type="pmid">17102051</pub-id></mixed-citation>
      </ref>
      <ref id="bibr14-1553350612438416">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aydin</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name></person-group>
<article-title>The changing face of renal cell carcinoma
pathology</article-title>. <source>Curr Oncol Rep</source>.
<year>2008</year>;<volume>10</volume>:<fpage>235</fpage>-<lpage>244</lpage><pub-id pub-id-type="pmid">18765154</pub-id></mixed-citation>
      </ref>
      <ref id="bibr15-1553350612438416">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oosterwijk</surname><given-names>E</given-names></name><name><surname>Ruiter</surname><given-names>DJ</given-names></name><name><surname>Hoedemaeker</surname><given-names>PJ</given-names></name><etal/></person-group>
<article-title>Monoclonal antibody G 250 recognizes a determinant present
in renal-cell carcinoma and absent from normal kidney</article-title>. <source>Int J
Cancer</source>.
<year>1986</year>;<volume>38</volume>:<fpage>489</fpage>-<lpage>494</lpage><pub-id pub-id-type="pmid">2428759</pub-id></mixed-citation>
      </ref>
      <ref id="bibr16-1553350612438416">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oosterwijk</surname><given-names>E</given-names></name></person-group>
<article-title>Carbonic anhydrase IX: historical and future
perspectives</article-title>. <source>BJU Int</source>.
<year>2008</year>;<volume>101</volume>(<issue>suppl
4</issue>):<fpage>2</fpage>-<lpage>7</lpage><pub-id pub-id-type="pmid">18430115</pub-id></mixed-citation>
      </ref>
      <ref id="bibr17-1553350612438416">
        <label>17.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grawitz</surname><given-names>P</given-names></name></person-group>
<article-title>Die sogenannten Lipome der Niere</article-title>.
<source>Virchows Archiv f&#xFC;r pathologische Anatomie und Physiologie, und f&#xFC;r klinische
Medicin</source>.
<year>1883</year>;<volume>93</volume>:<fpage>39</fpage>-<lpage>63</lpage></mixed-citation>
      </ref>
      <ref id="bibr18-1553350612438416">
        <label>18.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mccormick</surname><given-names>WF</given-names></name><name><surname>Blake</surname><given-names>CC</given-names></name></person-group>
<article-title>Some notes on Paul Grawitz and his tumor</article-title>.
<source>Cancer</source>.
<year>1958</year>;<volume>11</volume>:<fpage>871</fpage>-<lpage>872</lpage><pub-id pub-id-type="pmid">13585339</pub-id></mixed-citation>
      </ref>
      <ref id="bibr19-1553350612438416">
        <label>19.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stillebroer</surname><given-names>AB</given-names></name><name><surname>Mulders</surname><given-names>PF</given-names></name><name><surname>Boerman</surname><given-names>OC</given-names></name><name><surname>Oyen</surname><given-names>WJ</given-names></name><name><surname>Oosterwijk</surname><given-names>E</given-names></name></person-group>
<article-title>Carbonic anhydrase IX in renal cell carcinoma:
implications for prognosis, diagnosis, and therapy</article-title>. <source>Eur
Urol</source>.
<year>2010</year>;<volume>58</volume>:<fpage>75</fpage>-<lpage>83</lpage><pub-id pub-id-type="pmid">20359812</pub-id></mixed-citation>
      </ref>
      <ref id="bibr20-1553350612438416">
        <label>20.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Opavsk&#xFD;</surname><given-names>R</given-names></name><name><surname>Pastorekov&#xE1;</surname><given-names>S</given-names></name><name><surname>Zeln&#xED;k</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Human MN/CA9 gene, a novel member of the carbonic
anhydrase family: structure and exon to protein domain relationships</article-title>.
<source>Genomics</source>.
<year>1996</year>;<volume>33</volume>:<fpage>480</fpage>-<lpage>487</lpage><pub-id pub-id-type="pmid">8661007</pub-id></mixed-citation>
      </ref>
      <ref id="bibr21-1553350612438416">
        <label>21.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leibovich</surname><given-names>BC</given-names></name><name><surname>Sheinin</surname><given-names>Y</given-names></name><name><surname>Lohse</surname><given-names>CM</given-names></name><etal/></person-group>
<article-title>Carbonic anhydrase IX is not an independent predictor of
outcome for patients with clear cell renal cell carcinoma</article-title>. <source>J
Clin Oncol</source>.
<year>2007</year>;<volume>25</volume>:<fpage>4757</fpage>-<lpage>4764</lpage><pub-id pub-id-type="pmid">17947723</pub-id></mixed-citation>
      </ref>
      <ref id="bibr22-1553350612438416">
        <label>22.</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Supuran</surname><given-names>CT</given-names></name></person-group>
<article-title>Carbonic anhydrases: catalytic and inhibition mechanisms,
distribution and physiological roles</article-title>. In: <person-group person-group-type="editor"><name><surname>Supuran</surname><given-names>CT</given-names></name><name><surname>Scozzafava</surname><given-names>A</given-names></name><name><surname>Conway</surname><given-names>J</given-names></name></person-group>, eds. <source>Carbonic Anhydrase: Its Inhibitors and Activators</source>.
<publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>CRC
Press</publisher-name>; <year>2004</year>:<fpage>1</fpage>-<lpage>23</lpage></mixed-citation>
      </ref>
      <ref id="bibr23-1553350612438416">
        <label>23.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wykoff</surname><given-names>CC</given-names></name><name><surname>Beasley</surname><given-names>NJ</given-names></name><name><surname>Watson</surname><given-names>PH</given-names></name><etal/></person-group>
<article-title>Hypoxia-inducible expression of tumor-associated carbonic
anhydrases</article-title>. <source>Cancer Res</source>.
<year>2000</year>;<volume>60</volume>:<fpage>7075</fpage>-<lpage>7083</lpage><pub-id pub-id-type="pmid">11156414</pub-id></mixed-citation>
      </ref>
      <ref id="bibr24-1553350612438416">
        <label>24.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rice</surname><given-names>SL</given-names></name><name><surname>Roney</surname><given-names>CA</given-names></name><name><surname>Daumar</surname><given-names>P</given-names></name><name><surname>Lewis</surname><given-names>JS</given-names></name></person-group>
<article-title>The next generation of positron emission tomography
radiopharmaceuticals in oncology</article-title>. <source>Semin Nucl Med</source>.
<year>2011</year>;<volume>41</volume>:<fpage>265</fpage>-<lpage>282</lpage><pub-id pub-id-type="pmid">21624561</pub-id></mixed-citation>
      </ref>
      <ref id="bibr25-1553350612438416">
        <label>25.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bui</surname><given-names>MH</given-names></name><name><surname>Seligson</surname><given-names>D</given-names></name><name><surname>Han</surname><given-names>KR</given-names></name><etal/></person-group>
<article-title>Carbonic anhydrase IX is an independent predictor of
survival in advanced renal clear cell carcinoma: implications for prognosis and
therapy</article-title>. <source>Clin Cancer Res</source>.
<year>2003</year>;<volume>9</volume>:<fpage>802</fpage>-<lpage>811</lpage><pub-id pub-id-type="pmid">12576453</pub-id></mixed-citation>
      </ref>
      <ref id="bibr26-1553350612438416">
        <label>26.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Phuoc</surname><given-names>NB</given-names></name><name><surname>Ehara</surname><given-names>H</given-names></name><name><surname>Gotoh</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Prognostic value of the co-expression of carbonic
anhydrase IX and vascular endothelial growth factor in patients with clear cell renal
cell carcinoma</article-title>. <source>Oncol Rep</source>.
<year>2008</year>;<volume>20</volume>:<fpage>525</fpage>-<lpage>530</lpage><pub-id pub-id-type="pmid">18695901</pub-id></mixed-citation>
      </ref>
      <ref id="bibr27-1553350612438416">
        <label>27.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liao</surname><given-names>SY</given-names></name><name><surname>Aurelio</surname><given-names>ON</given-names></name><name><surname>Jan</surname><given-names>K</given-names></name><name><surname>Zavada</surname><given-names>J</given-names></name><name><surname>Stanbridge</surname><given-names>EJ</given-names></name></person-group>
<article-title>Identification of the MN/CA9 protein as a reliable
diagnostic biomarker of clear cell carcinoma of the kidney</article-title>.
<source>Cancer Res</source>.
<year>1997</year>;<volume>57</volume>:<fpage>2827</fpage>-<lpage>2831</lpage><pub-id pub-id-type="pmid">9230182</pub-id></mixed-citation>
      </ref>
      <ref id="bibr28-1553350612438416">
        <label>28.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grabmaier</surname><given-names>K</given-names></name><name><surname>Vissers</surname><given-names>JL</given-names></name><name><surname>De Weijert</surname><given-names>MC</given-names></name><etal/></person-group>
<article-title>Molecular cloning and immunogenicity of renal cell
carcinoma-associated antigen G250</article-title>. <source>Int J Cancer</source>.
<year>2000</year>;<volume>85</volume>:<fpage>865</fpage>-<lpage>870</lpage><pub-id pub-id-type="pmid">10709109</pub-id></mixed-citation>
      </ref>
      <ref id="bibr29-1553350612438416">
        <label>29.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bismar</surname><given-names>TA</given-names></name><name><surname>Bianco</surname><given-names>FJ</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Quantification of G250 mRNA expression in renal epithelial
neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin
sections</article-title>. <source>Pathology</source>.
<year>2003</year>;<volume>35</volume>:<fpage>513</fpage>-<lpage>517</lpage><pub-id pub-id-type="pmid">14660102</pub-id></mixed-citation>
      </ref>
      <ref id="bibr30-1553350612438416">
        <label>30.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oosterwijk</surname><given-names>E</given-names></name><name><surname>Debruyne</surname><given-names>FM</given-names></name></person-group>
<article-title>Radiolabeled monoclonal antibody G250 in renal-cell
carcinoma</article-title>. <source>World J Urol</source>.
<year>1995</year>;<volume>13</volume>:<fpage>186</fpage>-<lpage>190</lpage><pub-id pub-id-type="pmid">7550393</pub-id></mixed-citation>
      </ref>
      <ref id="bibr31-1553350612438416">
        <label>31.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oosterwijk</surname><given-names>E</given-names></name><name><surname>Bander</surname><given-names>NH</given-names></name><name><surname>Divgi</surname><given-names>CR</given-names></name><etal/></person-group>
<article-title>Antibody localization in human renal cell carcinoma: a
phase I study of monoclonal antibody G250</article-title>. <source>J Clin
Oncol</source>.
<year>1993</year>;<volume>11</volume>:<fpage>738</fpage>-<lpage>750</lpage><pub-id pub-id-type="pmid">8478666</pub-id></mixed-citation>
      </ref>
      <ref id="bibr32-1553350612438416">
        <label>32.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steffens</surname><given-names>MG</given-names></name><name><surname>Boerman</surname><given-names>OC</given-names></name><name><surname>Oosterwijk-Wakka</surname><given-names>JC</given-names></name><etal/></person-group>
<article-title>Targeting of renal cell carcinoma with iodine-131-labeled
chimeric monoclonal antibody G250</article-title>. <source>J Clin Oncol</source>.
<year>1997</year>;<volume>15</volume>:<fpage>1529</fpage>-<lpage>1537</lpage><pub-id pub-id-type="pmid">9193349</pub-id></mixed-citation>
      </ref>
      <ref id="bibr33-1553350612438416">
        <label>33.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steffens</surname><given-names>MG</given-names></name><name><surname>Boerman</surname><given-names>OC</given-names></name><name><surname>de Mulder</surname><given-names>PH</given-names></name><etal/></person-group>
<article-title>Phase I radioimmunotherapy of metastatic renal cell
carcinoma with <sup>131</sup>I-labeled chimeric monoclonal antibody
G250</article-title>. <source>Clin Cancer Res</source>.
<year>1999</year>;<volume>5</volume>(<issue>10
suppl</issue>):<fpage>3268s</fpage>-<lpage>3274s</lpage><pub-id pub-id-type="pmid">10541374</pub-id></mixed-citation>
      </ref>
      <ref id="bibr34-1553350612438416">
        <label>34.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brouwers</surname><given-names>AH</given-names></name><name><surname>Dorr</surname><given-names>U</given-names></name><name><surname>Lang</surname><given-names>O</given-names></name><etal/></person-group>
<article-title><sup>131</sup>I-cG250 monoclonal antibody
immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell
carcinoma: a comparative study</article-title>. <source>Nucl Med Commun</source>.
<year>2002</year>;<volume>23</volume>:<fpage>229</fpage>-<lpage>236</lpage><pub-id pub-id-type="pmid">11891480</pub-id></mixed-citation>
      </ref>
      <ref id="bibr35-1553350612438416">
        <label>35.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brouwers</surname><given-names>AH</given-names></name><name><surname>Buijs</surname><given-names>WC</given-names></name><name><surname>Oosterwijk</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Targeting of metastatic renal cell carcinoma with the
chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient
comparison</article-title>. <source>Clin Cancer Res</source>.
<year>2003</year>;<volume>9</volume>(<issue>10 pt
2</issue>):<fpage>3953S</fpage>-<lpage>3960S</lpage><pub-id pub-id-type="pmid">14506194</pub-id></mixed-citation>
      </ref>
      <ref id="bibr36-1553350612438416">
        <label>36.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brouwers</surname><given-names>AH</given-names></name><name><surname>Mulders</surname><given-names>PF</given-names></name><name><surname>de Mulder</surname><given-names>PH</given-names></name><etal/></person-group>
<article-title>Lack of efficacy of two consecutive treatments of
radioimmunotherapy with <sup>131</sup>I-cG250 in patients with metastasized clear cell
renal cell carcinoma</article-title>. <source>J Clin Oncol</source>.
<year>2005</year>;<volume>23</volume>:<fpage>6540</fpage>-<lpage>6548</lpage><pub-id pub-id-type="pmid">16170161</pub-id></mixed-citation>
      </ref>
      <ref id="bibr37-1553350612438416">
        <label>37.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brouwers</surname><given-names>AH</given-names></name><name><surname>Mulders</surname><given-names>PF</given-names></name><name><surname>Oyen</surname><given-names>WJ</given-names></name></person-group>
<article-title>Carbonic anhydrase IX expression in clear cell renal cell
carcinoma and normal tissues: experiences from (radio) immunotherapy</article-title>.
<source>J Clin Oncol</source>.
<year>2008</year>;<volume>26</volume>:<fpage>3808</fpage>-<lpage>3809</lpage>; author
reply 3811-3812.<pub-id pub-id-type="pmid">18669472</pub-id></mixed-citation>
      </ref>
      <ref id="bibr38-1553350612438416">
        <label>38.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pentlow</surname><given-names>KS</given-names></name><name><surname>Graham</surname><given-names>MC</given-names></name><name><surname>Lambrecht</surname><given-names>RM</given-names></name><etal/></person-group>
<article-title>Quantitative imaging of iodine-124 with
PET</article-title>. <source>J Nucl Med</source>.
<year>1996</year>;<volume>37</volume>:<fpage>1557</fpage>-<lpage>1562</lpage><pub-id pub-id-type="pmid">8790218</pub-id></mixed-citation>
      </ref>
      <ref id="bibr39-1553350612438416">
        <label>39.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herzog</surname><given-names>H</given-names></name><name><surname>Tellman</surname><given-names>L</given-names></name><name><surname>Qaim</surname><given-names>SM</given-names></name><name><surname>Spellerberg</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>A</given-names></name><name><surname>Coenen</surname><given-names>HH</given-names></name></person-group>
<article-title>PET quantitation and imaging of the non-pure
positron-emitting iodine isotope 124I</article-title>. <source>Appl Radiat
Isot</source>.
<year>2002</year>;<volume>56</volume>:<fpage>673</fpage>-<lpage>679</lpage><pub-id pub-id-type="pmid">11993941</pub-id></mixed-citation>
      </ref>
      <ref id="bibr40-1553350612438416">
        <label>40.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Divgi</surname><given-names>CR</given-names></name><name><surname>Pandit-Taskar</surname><given-names>N</given-names></name><name><surname>Jungbluth</surname><given-names>AA</given-names></name><etal/></person-group>
<article-title>Preoperative characterisation of clear-cell renal
carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in
patients with renal masses: a phase I trial</article-title>. <source>Lancet
Oncol</source>.
<year>2007</year>;<volume>8</volume>:<fpage>304</fpage>-<lpage>310</lpage><pub-id pub-id-type="pmid">17395103</pub-id></mixed-citation>
      </ref>
      <ref id="bibr41-1553350612438416">
        <label>41.</label>
        <mixed-citation publication-type="gov">
<person-group person-group-type="author"><name><surname>Leung</surname><given-names>K</given-names></name></person-group>
<article-title><sup>124</sup>I-chimeric monoclonal antibody
G250</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK43528/">http://www.ncbi.nlm.nih.gov/books/NBK43528/</ext-link> Last updated <month>5</month>
<day>20</day>, <year>2010</year>
<date-in-citation>Accessed October 5,
2011</date-in-citation></mixed-citation>
      </ref>
      <ref id="bibr42-1553350612438416">
        <label>42.</label>
        <mixed-citation publication-type="gov">
<article-title>A comparative study of PET/CT versus diagnostic ct for the detection of
clear cell renal cell carcinoma in pre-surgical patients with renal masses using
iodine-124 labeled chimeric G250 (124I-cG250)</article-title>. <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00606632">http://clinicaltrials.gov/ct2/show/NCT00606632</ext-link>
<date-in-citation>Accessed
October 5, 2011</date-in-citation></mixed-citation>
      </ref>
      <ref id="bibr43-1553350612438416">
        <label>43.</label>
        <mixed-citation publication-type="webpage">
<collab>IBA/Wilex</collab>
<article-title>Redectane: pre-BLA meeting with
FDA</article-title>, <day>17</day>
<month>6</month>
<year>2011</year>
<ext-link ext-link-type="uri" xlink:href="http://www.wilex.de/pdf/Download/20110617_WILEX_REDECTANE_PreBLA_Press_Analyst_presentation.pdf">http://www.wilex.de/pdf/Download/20110617_WILEX_REDECTANE_PreBLA_Press_Analyst_presentation.pdf</ext-link>
<date-in-citation>Accessed October 5, 2011</date-in-citation></mixed-citation>
      </ref>
      <ref id="bibr44-1553350612438416">
        <label>44.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Uzzo</surname><given-names>R</given-names></name><name><surname>Russo</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Multicenter phase 3 REDECT trial with iodine I 124
Girentuximab-PET/CT for the presurgical detection of clear cell renal cell carcinoma
(ccRCC) [abstract]</article-title>. <source>Kidney Cancer J</source>.
<year>2010</year>;<volume>8</volume>:<volume>79</volume>, <fpage>85</fpage></mixed-citation>
      </ref>
      <ref id="bibr45-1553350612438416">
        <label>45.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Strong</surname><given-names>VE</given-names></name><name><surname>Humm</surname><given-names>J</given-names></name><name><surname>Russo</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>A novel method to localize antibody-targeted cancer
deposits intraoperatively using handheld PET beta and gamma probes</article-title>.
<source>Surg Endosc</source>.
<year>2008</year>;<volume>22</volume>:<fpage>386</fpage>-<lpage>391</lpage><pub-id pub-id-type="pmid">18027053</pub-id></mixed-citation>
      </ref>
      <ref id="bibr46-1553350612438416">
        <label>46.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bahnson</surname><given-names>EE</given-names></name><name><surname>Murrey</surname><given-names>DA</given-names></name><name><surname>Mojzisik</surname><given-names>CM</given-names></name><etal/></person-group>
<article-title>PET/CT imaging of clear cell renal cell carcinoma with
<sup>124</sup>I labeled chimeric antibody</article-title>. <source>Ther Adv
Urol</source>.
<year>2009</year>;<volume>1</volume>:<fpage>67</fpage>-<lpage>70</lpage><pub-id pub-id-type="pmid">21789055</pub-id></mixed-citation>
      </ref>
      <ref id="bibr47-1553350612438416">
        <label>47.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murrey</surname><given-names>DA</given-names></name><name><surname>Bahnson</surname><given-names>EE</given-names></name><name><surname>Mojzisik</surname><given-names>CM</given-names></name><etal/></person-group>
<article-title>Validation of targeted molecular imaging using surgical
specimens: a feasibility assessment using 124I-cG250 monoclonal antibody PET/CT in clear
cell renal cell carcinoma</article-title>. <source>J Am Coll Surg</source>.
<year>2009</year>;<volume>209</volume>:<fpage>s128</fpage></mixed-citation>
      </ref>
      <ref id="bibr48-1553350612438416">
        <label>48.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hall</surname><given-names>NC</given-names></name><name><surname>Povoski</surname><given-names>SP</given-names></name><name><surname>Murrey</surname><given-names>DA</given-names></name><name><surname>Knopp</surname><given-names>MV</given-names></name><name><surname>Martin</surname><given-names>EW</given-names></name></person-group>
<article-title>Combined approach of perioperative <sup>18</sup>F-FDG
PET/CT imaging and intraoperative <sup>18</sup>F-FDG handheld gamma probe detection for
tumor localization and verification of complete tumor resection in breast
cancer</article-title>. <source>World J Surg Oncol</source>.
<year>2007</year>;<volume>5</volume>:<fpage>143</fpage><pub-id pub-id-type="pmid">18154677</pub-id></mixed-citation>
      </ref>
      <ref id="bibr49-1553350612438416">
        <label>49.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Povoski</surname><given-names>SP</given-names></name><name><surname>Hall</surname><given-names>NC</given-names></name><name><surname>Walker</surname><given-names>MJ</given-names></name><name><surname>Martin</surname><given-names>EW</given-names></name></person-group>
<article-title>Multimodality approach of perioperative <sup>18</sup>F-FDG
PET/CT imaging, intraoperative <sup>18</sup>F-FDG handheld gamma probe detection, and
intraoperative ultrasound for tumor localization and verification of resection of all
sites of hypermetabolic activity in a case of occult recurrent metastatic
melanoma</article-title>. <source>World J Surg Oncol</source>.
<year>2008</year>;<volume>6</volume>:<fpage>1</fpage><pub-id pub-id-type="pmid">18186915</pub-id></mixed-citation>
      </ref>
      <ref id="bibr50-1553350612438416">
        <label>50.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hall</surname><given-names>NC</given-names></name><name><surname>Povoski</surname><given-names>SP</given-names></name><name><surname>Murrey</surname><given-names>DA</given-names><suffix>Jr</suffix></name><name><surname>Knopp</surname><given-names>MV</given-names></name><name><surname>Martin</surname><given-names>EW</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Bringing advanced medical imaging into the operative arena
could revolutionize the surgical care of cancer patients</article-title>. <source>Expert
Rev Med Devices</source>.
<year>2008</year>;<volume>5</volume>:<fpage>663</fpage>-<lpage>667</lpage><pub-id pub-id-type="pmid">19025340</pub-id></mixed-citation>
      </ref>
      <ref id="bibr51-1553350612438416">
        <label>51.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Povoski</surname><given-names>SP</given-names></name><name><surname>Hall</surname><given-names>NC</given-names></name><name><surname>Murrey</surname><given-names>DA</given-names><suffix>Jr</suffix></name><etal/></person-group>
<article-title>Multimodal imaging and detection approach to
<sup>18</sup>F-FDG-directed surgery for patients with known or suspected malignancies: A
comprehensive description of the specific methodology utilized in a single-institution
cumulative retrospective experience</article-title>. <source>World J Surg
Oncol</source>. <year>2011</year>;<volume>9</volume>:<fpage>152</fpage><pub-id pub-id-type="pmid">22112047</pub-id></mixed-citation>
      </ref>
      <ref id="bibr52-1553350612438416">
        <label>52.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Otsuka</surname><given-names>H</given-names></name><name><surname>Graham</surname><given-names>M</given-names></name><name><surname>Kubo</surname><given-names>A</given-names></name><name><surname>Nishitani</surname><given-names>H</given-names></name></person-group>
<article-title>Clinical utility of FDG PET</article-title>. <source>J Med
Invest</source>.
<year>2004</year>;<volume>51</volume>:<fpage>14</fpage>-<lpage>19</lpage><pub-id pub-id-type="pmid">15000251</pub-id></mixed-citation>
      </ref>
      <ref id="bibr53-1553350612438416">
        <label>53.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Endo</surname><given-names>K</given-names></name><name><surname>Oriuchi</surname><given-names>N</given-names></name><name><surname>Higuchi</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>PET and PET/CT using 18F-FDG in the diagnosis and
management of cancer patients</article-title>. <source>Int J Clin Oncol</source>.
<year>2006</year>;<volume>11</volume>:<fpage>286</fpage>-<lpage>296</lpage><pub-id pub-id-type="pmid">16937302</pub-id></mixed-citation>
      </ref>
      <ref id="bibr54-1553350612438416">
        <label>54.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>A</given-names></name><name><surname>Gonz&#xE1;lez-Alenda</surname><given-names>FJ</given-names></name><name><surname>Alonso</surname><given-names>M</given-names></name><name><surname>Sierra</surname><given-names>JM</given-names></name></person-group>
<article-title>PET-CT in clinical oncology</article-title>. <source>Clin
Transl Oncol</source>.
<year>2007</year>;<volume>9</volume>:<fpage>494</fpage>-<lpage>505</lpage><pub-id pub-id-type="pmid">17720652</pub-id></mixed-citation>
      </ref>
      <ref id="bibr55-1553350612438416">
        <label>55.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Otsuka</surname><given-names>H</given-names></name><name><surname>Morita</surname><given-names>N</given-names></name><name><surname>Yamashita</surname><given-names>K</given-names></name><name><surname>Nishitani</surname><given-names>H</given-names></name></person-group>
<article-title>FDG-PET/CT for cancer management</article-title>.
<source>J Med Invest</source>.
<year>2007</year>;<volume>54</volume>:<fpage>195</fpage>-<lpage>199</lpage><pub-id pub-id-type="pmid">17878667</pub-id></mixed-citation>
      </ref>
      <ref id="bibr56-1553350612438416">
        <label>56.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vallabhajosula</surname><given-names>S</given-names></name></person-group>
<article-title>(18)F-labeled positron emission tomographic
radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor
localization</article-title>. <source>Semin Nucl Med</source>.
<year>2007</year>;<volume>37</volume>:<fpage>400</fpage>-<lpage>419</lpage><pub-id pub-id-type="pmid">17920348</pub-id></mixed-citation>
      </ref>
      <ref id="bibr57-1553350612438416">
        <label>57.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Poeppel</surname><given-names>TD</given-names></name><name><surname>Krause</surname><given-names>BJ</given-names></name><name><surname>Heusner</surname><given-names>TA</given-names></name><name><surname>Boy</surname><given-names>C</given-names></name><name><surname>Bockisch</surname><given-names>A</given-names></name><name><surname>Antoch</surname><given-names>G</given-names></name></person-group>
<article-title>PET/CT for the staging and follow-up of patients with
malignancies</article-title>. <source>Eur J Radiol</source>.
<year>2009</year>;<volume>70</volume>:<fpage>382</fpage>-<lpage>392</lpage><pub-id pub-id-type="pmid">19406595</pub-id></mixed-citation>
      </ref>
      <ref id="bibr58-1553350612438416">
        <label>58.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pauwels</surname><given-names>EK</given-names></name><name><surname>Ribeiro</surname><given-names>MJ</given-names></name><name><surname>Stoot</surname><given-names>JH</given-names></name><name><surname>McCready</surname><given-names>VR</given-names></name><name><surname>Bourguignon</surname><given-names>M</given-names></name><name><surname>Mazi&#xE8;re</surname><given-names>B</given-names></name></person-group>
<article-title>FDG accumulation and tumor biology</article-title>.
<source>Nucl Med Biol</source>.
<year>1998</year>;<volume>25</volume>:<fpage>317</fpage>-<lpage>322</lpage><pub-id pub-id-type="pmid">9639291</pub-id></mixed-citation>
      </ref>
      <ref id="bibr59-1553350612438416">
        <label>59.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shields</surname><given-names>AF</given-names></name><name><surname>Grierson</surname><given-names>JR</given-names></name><name><surname>Dohmen</surname><given-names>BM</given-names></name><etal/></person-group>
<article-title>Imaging proliferation in vivo with [F-18]FLT and positron
emission tomography</article-title>. <source>Nat Med</source>.
<year>1998</year>;<volume>4</volume>:<fpage>1334</fpage>-<lpage>1336</lpage><pub-id pub-id-type="pmid">9809561</pub-id></mixed-citation>
      </ref>
      <ref id="bibr60-1553350612438416">
        <label>60.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lind</surname><given-names>P</given-names></name><name><surname>Igerc</surname><given-names>I</given-names></name><name><surname>Beyer</surname><given-names>T</given-names></name><name><surname>Reinprecht</surname><given-names>P</given-names></name><name><surname>Hausegger</surname><given-names>K</given-names></name></person-group>
<article-title>Advantages and limitations of FDG PET in the follow-up of
breast cancer</article-title>. <source>Eur J Nucl Med Mol Imaging</source>.
<year>2004</year>;<volume>31</volume>(<issue>suppl 1</issue>):
<fpage>S125</fpage>-<lpage>S134</lpage><pub-id pub-id-type="pmid">15085295</pub-id></mixed-citation>
      </ref>
      <ref id="bibr61-1553350612438416">
        <label>61.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lim</surname><given-names>HS</given-names></name><name><surname>Yoon</surname><given-names>W</given-names></name><name><surname>Chung</surname><given-names>TW</given-names></name><etal/></person-group>
<article-title>FDG PET/CT for the detection and evaluation of breast
diseases: usefulness and limitations</article-title>. <source>Radiographics</source>.
<year>2007</year>;<volume>27</volume>(<issue>suppl 1</issue>):
<fpage>S197</fpage>-<lpage>S213</lpage><pub-id pub-id-type="pmid">18180227</pub-id></mixed-citation>
      </ref>
      <ref id="bibr62-1553350612438416">
        <label>62.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Metser</surname><given-names>U</given-names></name><name><surname>Even-Sapir</surname><given-names>E</given-names></name></person-group>
<article-title>Increased (18)F-fluorodeoxyglucose uptake in benign,
nonphysiologic lesions found on whole-body positron emission tomography/computed
tomography (PET/CT): accumulated data from four years of experience with
PET/CT</article-title>. <source>Semin Nucl Med</source>.
<year>2007</year>;<volume>37</volume>:<fpage>206</fpage>-<lpage>222</lpage><pub-id pub-id-type="pmid">17418153</pub-id></mixed-citation>
      </ref>
      <ref id="bibr63-1553350612438416">
        <label>63.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Bloomston</surname><given-names>M</given-names></name><name><surname>Hinkle</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Radioimmunoguided surgery (RIGS), PET/CT image-guided
surgery, and fluorescence image-guided surgery: past, present, and
future</article-title>. <source>J Surg Oncol</source>.
<year>2007</year>;<volume>96</volume>:<fpage>297</fpage>-<lpage>308</lpage><pub-id pub-id-type="pmid">17726663</pub-id></mixed-citation>
      </ref>
      <ref id="bibr64-1553350612438416">
        <label>64.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sch&#xF6;der</surname><given-names>H</given-names></name><name><surname>Moskowitz</surname><given-names>C</given-names></name></person-group>
<article-title>PET imaging for response assessment in lymphoma: potential
and limitations</article-title>. <source>Radiol Clin North Am</source>.
<year>2008</year>;<volume>46</volume>:<fpage>225</fpage>-<lpage>241</lpage><pub-id pub-id-type="pmid">18619378</pub-id></mixed-citation>
      </ref>
      <ref id="bibr65-1553350612438416">
        <label>65.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Povoski</surname><given-names>SP</given-names></name><name><surname>Neff</surname><given-names>RL</given-names></name><name><surname>Mojzisik</surname><given-names>CM</given-names></name><etal/></person-group>
<article-title>A comprehensive overview of radioguided surgery using
gamma detection probe technology</article-title>. <source>World J Surg Oncol</source>.
<year>2009</year>;<volume>7</volume>:<fpage>11</fpage><pub-id pub-id-type="pmid">19173715</pub-id></mixed-citation>
      </ref>
      <ref id="bibr66-1553350612438416">
        <label>66.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frangioni</surname><given-names>JV</given-names></name></person-group>
<article-title>The problem is background, not signal</article-title>.
<source>Mol Imaging</source>.
<year>2009</year>;<volume>8</volume>:<fpage>303</fpage>-<lpage>304</lpage><pub-id pub-id-type="pmid">20003888</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
